Business Description
Nutra Pharma Corp
NAICS : 325411
SIC : 2834
ISIN : US67060U2087
Total Employee Number:
7Description
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -27.98 | |||||
Debt-to-Equity | -0.58 | |||||
Debt-to-EBITDA | -17.25 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -215.13 | |||||
Beneish M-Score | -8.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.93 | |||||
9-Day RSI | 8.91 | |||||
14-Day RSI | 20.92 | |||||
3-1 Month Momentum % | -33.33 | |||||
12-1 Month Momentum % | 100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Days Inventory | 40.05 | |||||
Days Sales Outstanding | 51.76 | |||||
Days Payable | 1699.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -46.56 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.82 | |||||
Operating Margin % | -461.92 | |||||
Net Margin % | -341.49 | |||||
EBITDA Margin % | -179.57 | |||||
FCF Margin % | -336.53 | |||||
OCF Margin % | -336.53 | |||||
ROA % | -155.53 | |||||
ROIC % | -13.88 | |||||
3-Year ROIIC % | 25.49 | |||||
ROC (Joel Greenblatt) % | -1174.38 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
EV-to-EBIT | -16.2 | |||||
EV-to-EBITDA | -18.44 | |||||
EV-to-Revenue | 33.11 | |||||
EV-to-FCF | -9.84 | |||||
Earnings Yield (Greenblatt) % | -6.17 | |||||
FCF Yield % | -151.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NPHC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nutra Pharma Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.323 | ||
| EPS (TTM) ($) | - | ||
| Beta | 126.3697 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 2.92 | ||
| Volatility % | 479.01 | ||
| 14-Day RSI | 20.92 | ||
| 14-Day ATR ($) | 0.000055 | ||
| 20-Day SMA ($) | 0.00027 | ||
| 12-1 Month Momentum % | 100 | ||
| 52-Week Range ($) | 0.0001 - 0.005 | ||
| Shares Outstanding (Mil) | 7,159.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nutra Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nutra Pharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-11 | In 40 days | ||
| General meeting for 2025 | 2026-08-05 | In 3 days | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-05-20 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2026-04-06 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2026-03-25 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2025 | 2026-03-11 | 0.00 (+0.00%) | ||
| Annual report for 2024 | 2026-02-17 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2026-01-02 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2025-12-23 | 0.00 (+0.00%) |
Show
Entries
Nutra Pharma Corp Frequently Asked Questions
What is Nutra Pharma Corp(NPHC)'s stock price today?
The current price of NPHC is $0.00. The 52 week high of NPHC is $0.01 and 52 week low is $0.00.
When is next earnings date of Nutra Pharma Corp(NPHC)?
The next earnings date of Nutra Pharma Corp(NPHC) is 2026-09-11 Est..
Does Nutra Pharma Corp(NPHC) pay dividends? If so, how much?
Nutra Pharma Corp(NPHC) does not pay dividend.
Guru Commentaries on OTCPK:NPHC
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nutra Pharma Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers